MANNKIND CORP (MNKD) Stock Price & Overview
NASDAQ:MNKD • US56400P7069
The current stock price of MNKD is 2.775 USD. Today MNKD is down by -1.6%. In the past month the price decreased by -51.63%. In the past year, price decreased by -45.77%.
MNKD Key Statistics
- Market Cap
- 854.978M
- P/E
- 46.25
- Fwd P/E
- 52.10
- EPS (TTM)
- 0.06
- Dividend Yield
- N/A
MNKD Stock Performance
MNKD Stock Chart
MNKD Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MNKD. When comparing the yearly performance of all stocks, MNKD is a bad performer in the overall market: 94.68% of all stocks are doing better.
MNKD Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to MNKD. While MNKD is still in line with the averages on profitability rating, there are concerns on its financial health.
MNKD Earnings
On February 26, 2026 MNKD reported an EPS of -0.05 and a revenue of 111.95M. The company missed EPS expectations (-439.47% surprise) and beat revenue expectations (12.45% surprise).
MNKD Forecast & Estimates
15 analysts have analysed MNKD and the average price target is 9.8 USD. This implies a price increase of 253.27% is expected in the next year compared to the current price of 2.775.
For the next year, analysts expect an EPS growth of -6.55% and a revenue growth 34.43% for MNKD
MNKD Groups
Sector & Classification
MNKD Financial Highlights
Over the last trailing twelve months MNKD reported a non-GAAP Earnings per Share(EPS) of 0.06. The EPS decreased by -28.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.92% | ||
| ROA | 0.85% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MNKD Ownership
MNKD Latest News, Press Relases and Analysis
MNKD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.3 | 402.577B | ||
| AMGN | AMGEN INC | 16.28 | 203.574B | ||
| GILD | GILEAD SCIENCES INC | 16.52 | 181.247B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.77 | 125.079B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.17 | 81.897B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.64 | 42.495B | ||
| INSM | INSMED INC | N/A | 30.048B | ||
| BIIB | BIOGEN INC | 11.56 | 27.955B | ||
| NTRA | NATERA INC | N/A | 27.865B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.23 | 23.875B | ||
| MRNA | MODERNA INC | N/A | 22.105B | ||
| EXAS | EXACT SCIENCES CORP | 339.86 | 19.738B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.736B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MNKD
Company Profile
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The company is headquartered in Danbury, Connecticut and currently employs 592 full-time employees. The company went IPO on 2004-07-28. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Company Info
IPO: 2004-07-28
MANNKIND CORP
1 Casper Street
Danbury CONNECTICUT 91362 US
CEO: Michael E. Castagna
Employees: 592
Phone: 18186615000
MANNKIND CORP / MNKD FAQ
What does MNKD do?
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The company is headquartered in Danbury, Connecticut and currently employs 592 full-time employees. The company went IPO on 2004-07-28. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Can you provide the latest stock price for MANNKIND CORP?
The current stock price of MNKD is 2.775 USD. The price decreased by -1.6% in the last trading session.
What is the dividend status of MANNKIND CORP?
MNKD does not pay a dividend.
How is the ChartMill rating for MANNKIND CORP?
MNKD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the analyst forecast for MNKD stock?
15 analysts have analysed MNKD and the average price target is 9.8 USD. This implies a price increase of 253.27% is expected in the next year compared to the current price of 2.775.
When does MANNKIND CORP (MNKD) report earnings?
MANNKIND CORP (MNKD) will report earnings on 2026-05-06, after the market close.
Can you provide the ownership details for MNKD stock?
You can find the ownership structure of MANNKIND CORP (MNKD) on the Ownership tab.